

Candidate Selection of IL-2v-SAFA for the treatment of rare autoimmune disease

AprilBio



IMMUNOLOGY	Candidate
Product Type	Biologics (recombinant protein)
Indication	Inflammatory Bowel Disease (IBD) and Systemic Erythematosus Lupus (SLE)
Target	Regulatory T cells
MoA(Mechanism of Action)	<ul style="list-style-type: none"> - Selective activation and expansion of regulatory T cells through IL-2 receptor overexpressed on regulatory T cells - Extension of the half-life by utilizing FcRn-mediated recycling of serum albumin
Competitiveness	<ul style="list-style-type: none"> - Best-in-class - Selective activation and expansion of regulatory T cells without toxicity issues - Long-acting using SAFA technology
Development Stage	Candidate
Route of Administration	Subcutaneous administration